If you have money to invest into the Australian share market in August, then I think it could be worth splitting these funds evenly across the two ASX shares listed below.
Here's why I think they would be great options this month:
BetaShares Asia Technology Tigers ETF (ASX: ASIA)
I think that investing into this exchange traded fund could be a great idea. Given its growing middle class, I believe the Asian economy will grow very strongly over the next decade. This could make the BetaShares Asia Technology Tigers ETF a long term market beater. This is because this fund tracks the performance of the 50 largest technology and ecommerce companies that have their main area of business in Asia (excluding Japan). Among its holdings you'll find the likes of Alibaba, Samsung, and Tencent Holdings. The latter is the owner of the hugely popular WeChat app. It also recently became a major shareholder in buy now pay later juggernaut Afterpay Ltd (ASX: APT).
CSL Limited (ASX: CSL)
Due to a recent pullback in this biotherapeutics giant's shares, they are currently trading at a material discount to their 52-week high. The CSL share price weakness has been caused by concerns over its performance in FY 2021 due to difficulties collecting plasma during the pandemic. These collections are important as they are used to create some of its leading therapies. A shortage of plasma could drive prices higher and lead to margin compression. While this is certainly a risk, I'm optimistic the damage won't be anywhere near as bad as the market believes. In addition to this, I expect demand for flu vaccines to offset some or even all of any potential weakness. In light of this, I think investors ought to focus on its long term future, which I believe is remarkably positive. This is thanks to its leading therapies, recent acquisitions, and its high level of investment in research and development. The latter is underpinning a pipeline of very lucrative potential future therapies.
